ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Bradley Pharmaceuticals Announces Launch Of Authorized Generic Of Pamine(R) (methscopolamine Bromide)
Bradley
Pharmaceuticals, Inc. (NYSE: BDY) reported today that A. Aarons, Inc., a
subsidiary of Bradley Pharmaceuticals, has announced the launch of
methscopolamine bromide tablets, an authorized generic of the Company's
Pamine(R) tablets. The Company is currently accepting orders. The generic
product is available in both 2.5 mg and 5 mg forms, and will meet the same
level of quality and be manufactured with the same level of active and
inactive pharmaceutical ingredients as Pamine(R) branded products.
Pamine(R), currently marketed by Bradley through its Kenwood Therapeutics
Division, is indicated as adjunctive therapy for peptic ulcer.
Bradley Pharmaceuticals Chairman, President and CEO, Daniel Glassman
stated, "While Pamine (R) represented approximately 7% of Bradley Net
Sales, during the nine months ended September 30, 2006, we proactively
planned for this introduction and are pleased to be in a position to
successfully execute our strategy of extending the life cycles of our
established brands. The introduction of the Pamine(R) generic expands the
A. Aarons line of generic products offered to the wholesale and chain
pharmacy distribution channels. The A. Aarons subsidiary was launched in
January of 2006 and its presence in the generic market is beginning to grow
both in volume and acceptance. Consistent with other products that have
experienced generic competition in our portfolio, we will continue to
manufacture and distribute branded Pamine(R)."
Pamine(R) Tablets, like other anticholinergics, may produce drowsiness
or blurred vision. Patients should be cautioned regarding activities
requiring mental alertness, such as driving a motor vehicle or operating
machinery. Diarrhea may be an early symptom of incomplete intestinal
obstruction; in such cases, Pamine(R) is not appropriate treatment and may
be harmful. Use of Pamine(R) is contraindicated in patients with glaucoma,
blockage in the urinary tract, blockage in the gastrointestinal tract,
decreased gastrointestinal motility, unstable cardiovascular status in
acute hemorrhage, severe ulcerative colitis, paralytic ileus, toxic
megacolon complicating ulcerative colitis, and myasthenia gravis.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com.
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties in the
U.S. and 38 international markets. Bradley's success is based upon
strategically expanding from an Acquire, Enhance and Grow to an In-License,
Develop and Bring to Market business model: In-license phase II and phase
III drugs with long-term intellectual property protection; Develop these
products and submit completed clinical studies to the FDA for NDA approvals
and commercialization; Bring to Market these patent-protected brands to
fill unmet needs and leverage Bradley's marketing and sales expertise to
increase shareholder value. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in therapies for dermatology and podiatry;
Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and
other internal medicine brands; and A. Aarons, which markets authorized
generic versions of Doak and Kenwood therapies.
Important announcement:
Bradley Pharmaceuticals will present at the Wachovia Securities Small
and Mid-Cap Healthcare Conference, January 30, 2007, at 8:30 AM at the
Langham Hotel in the Timberlay Room, Boston MA.
Bradley Pharmaceuticals will present at the Roth Capital Partners 19th
Annual OC Conference, February 19-22, 2007, to be held at the Ritz Carlton
Laguna Niguel, CA.
Bradley Pharmaceuticals will present at the Raymond James & Associates
28th Annual Institutional Investors Conference, to be held at the Hyatt
Regency Grand Cypress in Orlando, FL, March 4-7, 2007.
Safe Harbor for Forward-Looking Statements
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or may
occur in the future, such as launches by Bradley of new products, market
acceptance of Bradley's products, sales and earnings estimates, other
predictions of financial performance, timing of payments on indebtedness,
timing and repurchases of shares of common stock, and the achievement of
initiatives to enhance corporate governance and long-term shareholder
value. Forward-looking statements are based on Bradley's experience and
perception of current conditions, trends, expected future developments and
other factors it believes are appropriate under the circumstances and are
subject to numerous risks and uncertainties, many of which are beyond
Bradley's control. These risks and uncertainties include Bradley's ability
to: successfully acquire, develop, integrate, or sell new products,
including POLYPHENON E(R) Ointment, Elestrin(TM) and the products
incorporating the delivery systems to be developed by Polymer Science;
estimate sales; comply with the restrictive covenants under its credit
facility; refinance its credit facility, if necessary; access the capital
markets on attractive terms or at all; favorably resolve the pending SEC
informal inquiry and file required financial statements with the SEC in a
timely manner; remediate its material weaknesses in its internal controls;
maintain sales of its products; or effectively react to other risks and
uncertainties described from time to time in Bradley's SEC filings, such as
fluctuation of quarterly financial results, estimation of product returns,
chargebacks, rebates and allowances, concentration of customers, reliance
on third party manufacturers and suppliers, litigation or other proceedings
(including the pending class action and shareholder derivative lawsuits),
government regulation, stock price volatility and ability to achieve
strategic initiatives to enhance long-term shareholder value. Further,
Bradley cannot accurately predict the impact on its business of the
approval, introduction, or expansion by competitors of generic or
therapeutically equivalent or comparable versions of Bradley's products or
of any other competing products. In addition, actual results may differ
materially from those projected. Bradley undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
http://www.bradpharm.com
View drug information on Elestrin; Estradiol.
Bradley Pharmaceuticals anunþã lansarea Autorizat Generic Din Pamine (R) (methscopolamine bromurã) - Bradley Pharmaceuticals Announces Launch Of Authorized Generic Of Pamine(R) (methscopolamine Bromide) - articole medicale engleza - startsanatate